(multidrug-resistant Pseudomonas aeruginosa; MDRP)
|
|
- Arabella Strickland
- 6 years ago
- Views:
Transcription
1 (multidrug-resistant Pseudomonas aeruginosa; MDRP) amikacin (AMK), imipenem/cilastatin (IPM), ciprofloxacin (CPFX) multidrug-resistant Pseudomonas aeruginosa (MDRP) CHROMagar TM Pseudomonas CHROMagar NAC agar 3 CHROM agar AMK 1 mg/ml, CPFX 1 mg/ml, IPM 4, 6 8 mg/ml NAC agar AMK 12 mg/ml, CPFX 1 mg/ml, IPM mg/ml CHROMagar AMK 1 mg/ml, CPFX 1 mg/ml, IPM 4 6 mg/ml MDRP Key words: MDRP, (Pseudomonas aeruginosa) 1) 1) 2 4) ( ) TEL: FAX: kumiko@met.nagoya-u.ac.jp 3 (multidrug-resistant P. aeruginosa; MDRP) 5) MDRP amikacin, imipenem/cilastatin ciprofloxacin MIC 32 mg/ml, 16 mg/ml 4 mg/ml 3) ) MDRP ) MDRP ) MDRP MDRP Vol. 19 No
2 MDRP 221 MDRP PCR 9, 10) methicillin-resistant Staphylococcus aureus (MRSA) vancomycinresistant Enterococcus 11 13) MDRP MDRP 3 MDRP 1. MDRP P. aeruginosa 93 Pseudomonas putida 3 Stenotrophomonas maltophilia 3 Burkholderia cepacia 3 Achromobacter xylosoxidans 3 Acinetobacter baumannii 3 Serratia marcescens 3 Providencia rettgeri 3 Enterobacter cloacae 3 Klebsiella oxytoca 3 Escherichia coli 3 API20E API20NE 37, 41, 44 P. aeruginosa PAO-1 PAO-1 2. MIC Clinical Laboratory Standards Institute (CLSI) 14) Mueller Hinton (M-H) amikacin (AMK) imipenem/cilastatin (IPM) ciprofloxacin (CPFX) 3 3. MDRP MDRP NAC agar CHROM agar TM Pseudomonas CHROM agar 11 McFarland No. 0.5 ( CFU/ml) 10 ml 2 37, McFarland No CFU/ml 5 2 M-H 50 ml 37 3 MDRP Break-point Checkerboard Plate MDRP 3 Break-point Checkerboard Plate MDRP 4 PAO-1 AMK, IPM, CPFX 3 Tateda 15) MIC MIC M-H 4 (1/4MIC 1/2MIC 1 MIC 2 MIC) M-H ml 2 IPM AMK, AMK CPFX, CPFX IPM Checkerboard Plate CFU/ml 10 ml 37 MIC Vol. 19 No
3 receiver operating characteristic curve; ROC 16 18) 1 AMK mg/ml, IPM mg/ ml, CPFX mg/ml 2 NAC agar CHROM agar non-mdrp MDRP CFU/ml 10 ml /MDRP 27 /non-mdrp NAC agar AMK 4, 8, 12, 16 mg/ml, IPM 12, 24, 36, 48, 64 mg/ml, CPFX 1, 2 mg/ ml 40 CHROM agar AMK 0.5, 1, 1.5, 2 mg/ml, IPM 2, 4, 6, 8, 12 mg/ml, CPFX 1, 2 mg/ml 40 non-mdrp 27 MDRP ROC MDRP MDRP ROC NAC agar 2 CHROM agar 3 93 MDRP29 5 M-H CFU/ml 5 50 ml CFU/ ml ml 5 1 1, 2, 3, CFU/ml non- MDRP 27 MDRP ml 37 MDRP non-mdrp 93 IPM, AMK CPFX MIC 3 53 (57.0 ) 1 IPM 17 CPFX 2 19 (20.5 ) 2 IPM AMK 1 IPM CPFX (19.4 ) (Table 1) (population) non-mdrp Vol. 19 No
4 MDRP 223 Table 1. Resistant rate of 93 clinically isolated P. aeruginosa for three antimicrobial agents Antimicrobial agents Number Resistant of isolates rate ( ) Susceptibility AMK drug-resistance IPM CPFX AMK, IPM drug-resistance AMK, CPFX IPM, CPFX drug-resistance AMK, IPM, CPFX non-mdrp MDRP 93 3 (3.2 ) non-mdrp Table 2 CHROM agar P. putida, S. maltophilia, S. marcescens, P. rettgeri, E. cloacae, E. coli NAC agar B. cepacia, S. marcescens, E. cloacae CHROM agar (Table 2) 2 NAC Table 2. Selective ability of two selective media for detecting P. aeruginosa Bacteria a) CHROM agar NAC agar Pseudomonas aeruginosa (3) Pseudomonas putida (3) Stenotrophomonas maltophilia (3) Burkholderia cepacia (3) b) Achromobacter xylosoxidans (3) Acinetobacter baumannii (3) Serratia marcescens (3) Providencia rettgeri (3) Enterobacter cloacae (3) Klebsiella oxytoca (3) Escherichia coli (3), All of three isolates grew on the selective media;, None of three isolates grew on the selective media. a) Values in parentheses indicate number of isolates tested. b) Plus minus ( ) indicates that one of three isolates was positive and the other isolates were negative. agar 10 3 CFU/ml CHROM agar 100 CFU/ml (Table 3) 3. Break-point Checkerboard Plate MDRP Break-point Checkerboard Plate 1 MIC Table 3. The detection limit of non-mdrp isolates on two selective media for detecting P. aeruginosa (n 5) Medium Growth of following dilution (No. of colonies) a) : Mueller Hinton agar (80) CHROM agar (680) (60) NAC agar (570) (76) (2), no growth;, less than 99 colonies;, colonies;, more than 1,000 colonies. a) Values in parentheses indicate mean number of colonies calculated from the results of five isolates. Vol. 19 No
5 MDRP ROC NAC agar AMK 12 mg/ ml, CPFX 1 mg/ml IPM mg/ml CHROM agar AMK 1 mg/ml, CPFX 1 mg/ml IPM 4, 6 8 mg/ml (Fig. 1) MDRP CHROM agar 5. MDRP 5.1. MDRP ROC 5 MDRP CHROM agar 300 CFU/ml AMK 1 mg/ml, CPFX 1 mg/ml IPM 4 mg/ml 6 mg/ml NAC agar MDRP 10 3 CFU/ml (Table 4) MDRP MDRP MDRP 3 non- Fig. 1. Analysis of the optimal concentrations of the antimicrobial agents by ROC curve. MDRP screening media were prepared by adding various combinations of antimicrobial agents into the CHROM or NAC agar. Then, the optimal concentrations of the three antimicrobial agents added to the media were determined using a ROC curve. Abbreviations: ROC, receiver operating characteristic; IPM, imipenem/cilastatin; AMK, amikacin; CPFX, ciprofloxacin. 26 Vol. 19 No
6 MDRP 225 MDRP 90 MDRP MDRP CHROM agar 97.8 NAC agar NAC agar 90.6 CHROM agar (Table 5) , 2, 3, 4 MDRP 4 (Table 6) Table 4. Detection limit of MDRP isolates on each MDRP screening medium (n 5) Medium Antimicrobial agents (mg/ml) Growth of following dilution (No. of colonies) b) : AMK IPM CPFX (280) Mueller Hinton agar (30 250) (20 250) CHROM agar a) ( ) (20 90) (50 410) (2 50) NAC agar a) ( ) (0 40), no growth;, less than 99 colonies;, colonies;, more than 1,000 colonies. a) The MDRP screening medium was prepared by adding various combinations of three antimicrobial agents into the CHROM agar or NAC agar. b) Values in parentheses indicate number of colonies calculated from the results of five isolates. Table 5. Sensitivity and specificity of each MDRP screening medium in 32 MDRP and 90 non-mdrp isolates Medium Antimicrobial agents (mg/ml) Positive culture/mdpr a) AMK IPM CPFX ( Sensitivity) Negative culture/non- MDRP ( Specificity) /32 (100) 88/90 (97.8) CHROM agar /32 (96.9) 88/90 (97.8) /32 (96.9) 88/90 (97.8) NAC agar /32 (90.6) 90/90 (100) /32 (90.6) 89/90 (98.9) a) MDRP isolates include 29 MDRP isolates distributed from National Institute of Infectious Diseases and 3 MDRP isolates selected from 93 clinical isolates collected in the present study. Table 6. Examination of the stability of each MDRP screening medium (a) NAC agar Preserved period Medium 1 Medium 2 Sensitivity ( ) Specificity ( ) Sensitivity ( ) Specificity ( ) 1 day week weeks weeks weeks Medium 1, AMK 12 mg/ml, IPM 12 mg/ml, CPFX 1 mg/ml; Medium 2, AMK 12 mg/ml, IPM 24 mg/ml, CPFX 1 mg/ml. Vol. 19 No
7 226 (b) CHROM agar Preserved period Medium 1 Medium 2 Medium 3 Sensitivity ( ) Specificity ( ) Sensitivity ( ) Specificity ( ) Sensitivity ( ) Specificity ( ) 1 day week weeks weeks weeks Medium 1, AMK 1 mg/ml, IPM 4 mg/ml, CPFX 1 mg/ml; Medium 2, AMK 1 mg/ml, IPM 6 mg/ml, CPFX 1 mg/ml; Medium 3, AMK 1 mg/ml, IPM 8 mg/ml, CPFX 1 mg/ml. MDRP MDRP MDRP 12) MDRP CHROM agar NAC agar NAC agar CHROM agar NAC agar Ike 16) MDRP ROC CHROM agar AMK 1 mg/ml, CPFX 1 mg/ml, IPM 4, 6 8 mg/ml 3 NAC agar AMK 12 mg/ml, CPFX 1 mg/ml, IPM mg/ml 2 CHROM agar MDRP (AMK 32 mg/ml, IPM 16 mg/ml, CPFX 4 mg/ml) Break-point Checkerboard Plate AMK, IPM, CPFX 3 Tateda 15) Cappelletty 20) CHROM agar ROC 5 MDRP MDRP MDRP3 non-mdrp 90 MDRP MRSA 11 13) NAC agar CFU/ml MDRP 28 Vol. 19 No
8 MDRP 227 CHROM agar 100 CFU/ml MDRP CHROM agar 125 / NAC agar 23 /1 1 5 AMK 1 mg/ml, IPM 4 6 mg/ml, CPFX 1 mg/ml ROC 17 19) ROC 3 MDRP MDRP MDRP MIC (golden standard) MRSA PCR meca golden standard MDRP AMK, IPM CPFX MIC MDRP 7 A. baumannii CHROMagar 21) OXA-23, -24, -51-like, -58-like MDRP MDRP ROC population population S. marcescens Pseudomonas population MDRP MDRP active surveillance MDRP MDRP 2.7 MDRP MDRP 1) Gomez, M. I., A. Prince Opportunistic infections in lung disease: Pseudomonas infections in cystic fibrosis. Curr. Opin. Pharmacol. 7: ) Kikuchi, T., G. Nagashima, K. Taguchi, et al Contaminated oral incubation equipment associated with an outbreak of carbapenem-resistant Pseudomonas in an intensive care unit. J. Hosp. Infect. 65: ) Sekiguchi, J., T. Asagi, T. Miyoshi-Akiyama, et al Outbreaks of multidrug-resistant Pseudomonas aeruginosa in community hospitals in Japan. J. Clin. Microbiol. 45: ) Galanos, C., M. A. Freudenberg, W. Reutter Galactosamine-induced sensitization to the lethal e#ects of endotoxin. Proc. Natl. Acad. Sci. U.S.A. 76: ) Tsuji, A., I. Kobayashi, T. Oguri, et al An Vol. 19 No
9 228 epidemiological study of the susceptibility and frequency of multiple-drug-resistant strains of Pseudomonas aeruginosa isolated at medical institutes nationwide in Japan. J. Infect. Chemother. 11: ) Livermore, D. M Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: Our worst nightmare? Clin. Infect. Dis. 34: ) Sekiguchi, J., T. Asagi, T. Miyoshi-Akiyama, et al Multidrug-resistant Pseudomonas aeruginosa strain that caused an outbreak in a neurosurgery ward and its aac(6 )-Iae gene cassette encoding a novel aminoglycoside acetyltransferase. Antimicrob. Agents Chemother. 49: ) Kirikae, T., Y. Mizuguchi, Y. Arakawa Investigation of isolation rates of Pseudomonas aeruginosa with and without multidrug resistance in medical facilities and clinical laboratories in Japan. J. Antimicrob. Chemother. 61: ) Ohara, M., S. Kouda, M. Onodera, et al Molecular characterization of imipenem-resistant Pseudomonas aeruginosa in Hiroshima, Japan. Microbiol. Immunol. 51: ) Shibata, N., Y. Doi, K. Yamane, et al PCR typing of genetic determinants for metallobeta-lactamases and integrases carried by gram-negative bacteria isolated in Japan, with focus on the class 3 integron. J. Clin. Microbiol. 41: ) Kluytmans, J., A. van Griethuysen, P. Willemse, et al Performance of CHROM agar selective medium and oxacillin resistance screening agar base for identifying Staphylococcus aureus and detecting methicillin resistance. J. Clin. Microbiol. 40: ) Nahimana, I., P. Francioli, D. S. Blanc Evaluation of three chromogenic media (MRSA-ID, MRSA-Select and CHROM agar MRSA) and ORSAB for surveillance cultures of methicillin-resistant Staphylococcus aureus. Clin. Microbiol. Infect. 12: ) Flayhart, D., J. F. Hindler, D. A. Bruckner, et al Multicenter evaluation of BBL CHROM agar MRSA medium for direct detection of methicillin-resistant Staphylococcus aureus from surveillance cultures of the anterior nares. J. Clin. Microbiol. 43: ) Clinical and Laboratory Standards Institute Performance and standards for antimicrobial susceptibility testing. Seventeen informational supplement. Document M100-S17. Clinical and Laboratory Standards Institute, Wayne, PA. 15) Tateda, K., Y. Ishii, T. Matsumoto Breakpoint Checkerboard Plate for screening of appropriate antibiotic combinations against multidrug-resistant Pseudomonas aeruginosa. Scand. J. Infect. Dis. 38: ) Ike, Y., Y. Arakawa, X. Ma, et al Nationwide survey shows that methicillin-resistant Staphylococcus aureus strains heterogeneously and intermediately resistant to vancomycin are not disseminated throughout Japanese hospitals. J. Clin. Microbiol. 39: ) 2007 p , 2 18) 2001 ROC (Vol. 1) 18: ) 2001 ROC (Vol. 2) 18: ) Cappelletty, D. M., M. J. Rybak Comparison of methodologies for synergism testing of drug combinations against resistant strains of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 40: ) Gordon, N. C., D. W. Wareham Evaluation of CHROMagar Acinetobacter for the detection of enteric carriage of multi-drug resistant Acinetobacter baumannii in critically III patients. J. Clin. Microbiol. 47: Vol. 19 No
10 MDRP 229 New Screening Medium Developed for Detecting Multidrug-resistant Pseudomonas aeruginosa Kumiko Kawamura Department of Medical Technology, Nagoya University School of Health Science Multidrug-resistant Pseudomonas aeruginosa (MDRP) is responsible for severe nosocomial infections, and rapid and accurate methods to detect such strains are needed. We developed a new MDRP screening medium by incorporation of three antimicrobial agents, amikacin (AMK), imipenem/cilastatin (IPM) and ciprofloxacin (CPFX), into selective mediums for the detection of Pseudomonas species such as CHROMagar TM Pseudomonas (CHROMagar) and NAC agar. The optimal concentrations of the three antimicrobial agents added to the selective mediums were determined using a receiver operating characteristic (ROC) curve. As the result, three kinds of CHROMagar with 1 mmg/ml of AMK, 4, 6 or 8 mg/ml of IPM and 1 mg/ml of CPFX (sensitivity of 88.9 and specificity of , respectively), and two kinds of NAC agar with 12 mg/ml of AMK, 12 or 24 mg/ml of IPM and 1 mg/ml of CPFX (sensitivity of , respectively, and specificity of 92.6 ), were selected as the optimal conditions for the detection of clinical MDRP isolates. The MDRP screening mediums based on the five conditions selected by ROC analysis were evaluated, and CHROMagar with 1 mmg/ml of AMK, 4 and 6 mg/ml of IPM and 1 mg/ml of CPFX showed the best detection limit (10 3 cfu/ml), sensitivity and specificity among the five conditions. Additionally, the stability of the medium was confirmed until four weeks at 4. The MDRP screening medium is a simple, rapid and cost-e#ective method compared to the conventional methods described in the literature. Thus, the use of the MDRP screening medium would make it possible to detect e$ciently MDRP isolates in clinical material. Vol. 19 No
1) 1) 1) 2) 2) (ICU) Key words: (ICU), ( ) 1 30 TEL: FAX: Vol. 17 No
2007 277 1) 1) 1) 2) 2) 3) 4) 5) 6) 1) 2) 3) 4) 5) 6) 18 10 17 19 8 20 16 7 1 (ICU) 20 2x 1.6 2.2 2SD 14 1 4 1 10 7 3 2 9 7.6; 95 2.37 24.62 6 4 5 1 DNA SpeI 9 2 A 7 B 2 A 3 B 1 ICU ICU 7 20 10 5 Key words:
More informationReceived 30 March 2005; returned 16 June 2005; revised 8 September 2005; accepted 12 September 2005
Journal of Antimicrobial Chemotherapy (2005) 56, 1047 1052 doi:10.1093/jac/dki362 Advance Access publication 20 October 2005 Evaluation of PPI-0903M (T91825), a novel cephalosporin: bactericidal activity,
More informationWhy some tests are no longer recommended
8 th July 2014 Why some tests are no longer recommended Robin A Howe, Cardiff, UK Antimicrobial use in Primary Care Tests that are no longer recommended Burkholderia cepacia complex testing Stenotrophomonas
More informationCefotaxime Rationale for the EUCAST clinical breakpoints, version th September 2010
Cefotaxime Rationale for the EUCAST clinical breakpoints, version 1.0 26 th September 2010 Foreword EUCAST The European Committee on Antimicrobial Susceptibility Testing (EUCAST) is organised by the European
More informationAuthor: Souha Kanj Andrew Whitelaw Michael J. Dowzicky. To appear in: International Journal of Antimicrobial Agents
t Title: In vitro activity of tigecycline and comparators against Gram-positive and Gram-negative isolates collected from the Middle East and Africa between 2004 and 2011 Author: Souha Kanj Andrew Whitelaw
More informationDetermining the Optimal Carbapenem MIC that Distinguishes Carbapenemase-Producing
AAC Accepted Manuscript Posted Online 8 August 2016 Antimicrob. Agents Chemother. doi:10.1128/aac.00838-16 Copyright 2016, American Society for Microbiology. All Rights Reserved. 1 1 2 Determining the
More informationDiscussion points CLSI M100 S19 Update. #1 format of tables has changed. #2 non susceptible category
Discussion points 2009 CLSI M100 S19 Update Nebraska Public Health Laboratory Changes most important to routine antimicrobial susceptibility testing. Documents available Janet Hindler discussion slide
More informationIn vitro and in vivo Pharmacodynamics of Colistin and Aztreonam Alone and in Combination against Multidrug-Resistant Pseudomonas aeruginosa
Antimicrobial Section / Original Paper Received: April 12, 2016 Accepted: August 23, 2016 Published online: October 28, 2016 In vitro and in vivo Pharmacodynamics of Colistin and Aztreonam Alone and in
More informationUniversity of Alberta Hospital Antibiogram for 2007 and 2008 Division of Medical Microbiology Department of Laboratory Medicine and Pathology
University of Alberta Hospital Antibiogram for 2007 and 2008 Division of Medical Microbiology Department of Laboratory Medicine and Pathology This material is supported in part by unrestricted educational
More informationSep Oct Nov Dec Total
LB PAGE 2 LB PAGE 3 Sep Oct Nov Dec 2007 2007 2007 2007 Total Repeat Information Total Repeats 35 15 17 9 76 Repeat Rate 6.01% 0.17% 1.12% 0.39% 2.07% Repeat Chemistry 25 0 2 0 27 Repeat Extraction 1 0
More informationExpert rules in antimicrobial susceptibility testing: State of the art
Expert rules in antimicrobial susceptibility testing: State of the art ESCMID Postgraduate Education Course Antimicrobial Susceptibility Testing and Surveillance: from Laboratory to Clinic Hospital Universitario
More informationDetection of NDM-1, VIM-1, KPC, OXA-48, and OXA-162 carbapenemases by MALDI- TOF mass spectrometry
JCM Accepts, published online ahead of print on 2 May 2012 J. Clin. Microbiol. doi:10.1128/jcm.01002-12 Copyright 2012, American Society for Microbiology. All Rights Reserved. 1 2 3 4 5 6 7 8 9 10 11 12
More information/01/$ DOI: /JCM Copyright 2001, American Society for Microbiology. All Rights Reserved.
JOURNAL OF CLINICAL MICROBIOLOGY, Jan. 2001, p. 183 190 Vol. 39, No. 1 0095-1137/01/$04.00 0 DOI: 10.1128/JCM.39.1.183 190.2001 Copyright 2001, American Society for Microbiology. All Rights Reserved. Contemporary
More informationAffinity of Doripenem and Comparators to Penicillin-Binding Proteins in Escherichia coli and ACCEPTED
AAC Accepts, published online ahead of print on February 00 Antimicrob. Agents Chemother. doi:./aac.01-0 Copyright 00, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights
More informationHealthcare-associated infections acquired in intensive care units
SURVEILLANCE REPORT Annual Epidemiological Report for 2015 Healthcare-associated infections acquired in intensive care units Key facts In 2015, 11 788 (8.3%) of patients staying in an intensive care unit
More informationConsultation on the Revision of Carbapenem Breakpoints
Consultation on the Revision of Carbapenem Breakpoints July 2018 Please send comments to the EUCAST Scientific Secretary at jturnidge@gmail.com by September 15. EUCAST revision of carbapenem breakpoints
More informationCarbapenem Disks on MacConkey agar as screening methods for the detection of. Carbapenem-Resistant Gram negative rods in stools.
JCM Accepts, published online ahead of print on 7 November 2012 J. Clin. Microbiol. doi:10.1128/jcm.02878-12 Copyright 2012, American Society for Microbiology. All Rights Reserved. 1 2 Carbapenem Disks
More informationDISEASE OUTBREAKS SUMMARY
DISEASE OUTBREAKS SUMMARY Outbreaks may be defined as (a) clusters of cases related in time and place or (b) occurrence of disease above a baseline or threshold level in a defined location. In Los Angeles
More informationTranslocation Studies Mid-Term Review (MTR) Meeting Marseille, France
Marie Curie Actions Research Training Networks (RTN) Translocation Studies Mid-Term Review (MTR) Meeting Marseille, France F. Vidal-Aroca, M.G.P. Page and J. Dreier Background Deteriorating situation regarding
More informationReceived 31 January 2011/Returned for modification 2 March 2011/Accepted 15 March 2011
JOURNAL OF CLINICAL MICROBIOLOGY, May 2011, p. 1965 1969 Vol. 49, No. 5 0095-1137/11/$12.00 doi:10.1128/jcm.00203-11 Copyright 2011, American Society for Microbiology. All Rights Reserved. Comparative
More informationAgainst Aerobic Gram-Negative Bacilli
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Dec. 1979, p. 6-6 0066-0/79/1-06/05$0.00/0 Vol., No. 6 In Vitro Activity of LY17935, a New 1-Oxa Cephalosporin, Against Aerobic Gram-Negative Bacilli DENNIS G. DELGADO,
More informationReduction in Workload and Reporting Time of MRSA Screening with MRSASelect. Medium versus Mannitol-Salt Medium Supplemented with Oxacillin ACCEPTED
JCM Accepts, published online ahead of print on 30 January 2008 J. Clin. Microbiol. doi:10.1128/jcm.01253-07 Copyright 2008, American Society for Microbiology and/or the Listed Authors/Institutions. All
More informationThis material is supported in part by unrestricted educational grants from: Abbott, Bayer HealthCare, Merck Frosst, Roche Diagnostics, and Wyeth Inc.
Division of Medical Microbiology Department of Laboratory Medicine and Pathology University of Alberta Hospital and Stollery Children's Hospital Antibiogram 2006 This material is supported in part by unrestricted
More informationALERT. Clinical microbiology considerations related to the emergence of. New Delhi metallo beta lactamases (NDM 1) and Klebsiella
ALERT Clinical microbiology considerations related to the emergence of New Delhi metallo beta lactamases (NDM 1) and Klebsiella pneumoniae carbapenemases (KPC) amongst hospitalized patients in South Africa
More informationCefuroxime iv Rationale for the EUCAST clinical breakpoints, version th September 2010
Cefuroxime iv Rationale for the EUCAST clinical breakpoints, version 1.0 26 th September 2010 Foreword EUCAST The European Committee on Antimicrobial Susceptibility Testing (EUCAST) is organised by the
More informationAAC Accepts, published online ahead of print on 13 October 2008 Antimicrob. Agents Chemother. doi: /aac
AAC Accepts, published online ahead of print on 13 October 2008 Antimicrob. Agents Chemother. doi:10.1128/aac.00931-08 Copyright 2008, American Society for Microbiology and/or the Listed Authors/Institutions.
More informationMHSAL Guidelines for the Prevention and Control of Antimicrobial Resistant Organisms (AROs) - Response to Questions
MHSAL Guidelines for the Prevention and Control of Antimicrobial Resistant Organisms (AROs) - Response to Questions Dr. Andrew Walkty Medical Microbiologist, Diagnostic Services Manitoba (DSM) June. 17,
More informationRecommendations for the Management of Carbapenem- Resistant Enterobacteriaceae (CRE) in Acute and Long-term Acute Care Hospitals
Recommendations for the Management of Carbapenem- Resistant Enterobacteriaceae (CRE) in Acute and Long-term Acute Care Hospitals Minnesota Department of Health 11/2011 Infectious Disease Epidemiology,
More informationLaboratory CLSI M100-S18 update. Paul D. Fey, Ph.D. Associate Professor/Associate Director Josh Rowland, M.T. (ASCP) State Training Coordinator
Nebraska Public Health Laboratory 2008 CLSI M100-S18 update Paul D. Fey, Ph.D. Associate Professor/Associate Director Josh Rowland, M.T. (ASCP) State Training Coordinator Agenda Discuss 2008 M100- S18
More informationAdenium Biotech. Management: - Peter Nordkild, MD, CEO, ex Novo Nordisk, Ferring, Egalet - Søren Neve, PhD, project director, ex Lundbeck, Novozymes
Adenium Biotech Management: - Peter Nordkild, MD, CEO, ex Novo Nordisk, Ferring, Egalet - Søren Neve, PhD, project director, ex Lundbeck, Novozymes Board of Directors: - Stephan Christgau, PhD, chairman,
More informationEvaluation of CHROMagar msupercarba for the detection of carbapenemaseproducing Gram-negative organisms
ORIGINAL ARTICLE Evaluation of CHROMagar msupercarba for the detection of carbapenemaseproducing Gram-negative organisms Julie Creighton and Hui Wang Canterbury Health Laboratories, Christchurch ABSTRACT
More informationSurveillance of antimicrobial susceptibility of Enterobacteriaceae pathogens isolated from intensive care units and surgical units in Russia
Feb. 2016 THE JAPANESE JOURNAL OF ANTIBIOTICS 69 1 41 41 Surveillance of antimicrobial susceptibility of Enterobacteriaceae pathogens isolated from intensive care units and surgical units in Russia IRINA
More informationScreening and detection of carbapenemases
Screening and detection of carbapenemases For many isolates with carbapenemases the MICs of carbapenems are around the susceptible breakpoint making resistance difficult to detect - particularly with automated
More informationEvaluation of Antibacterial Effect of Odor Eliminating Compounds
Evaluation of Antibacterial Effect of Odor Eliminating Compounds Yuan Zeng, Bingyu Li, Anwar Kalalah, Sang-Jin Suh, and S.S. Ditchkoff Summary Antibiotic activity of ten commercially available odor eliminating
More informationOutbreak investigation of nosocomial infections
Definitions Outbreak investigation of nosocomial infections School of Public Health, HSUM March 2012 Walter Popp, University Clinics Essen, Germany Epidemia increased number of cases, limited in time and
More informationIn-House Standardization of Carba NP Test for Carbapenemase Detection in Gram Negative Bacteria
International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 7 Number 01 (2018) Journal homepage: http://www.ijcmas.com Original Research Article https://doi.org/10.20546/ijcmas.2018.701.342
More informationDiagnosis of CPE: time to throw away those agar plates? Jon Otter, PhD FRCPath Guy s and St. Thomas NHS Foundation Trust / King s College London
Diagnosis of CPE: time to throw away those agar plates? Jon Otter, PhD FRCPath Guy s and St. Thomas NHS Foundation Trust / King s College London Disclosures I am employed part-time by Bioquell I have research
More informationAntibiotic Resistance Pattern of Blood and CSF Culture Isolates At NHLS Academic Laboratories (2005)
Antibiotic Resistance Pattern of Blood and CSF Culture Isolates At NHLS Academic Laboratories (2005) Streptococcus pneumoniae (SP) Blood Culture Isolates Penicillin intermediate Penicillin Cefotaxime 336
More informationComparison of CPS ID 3 and CHROMagar Orientation chromogenic agars with standard biplate technique for culture of clinical urine samples
J Microbiol Immunol Infect. 2008;41:422-427 Comparison of CPS ID 3 and CHROMagar Orientation chromogenic agars with standard biplate technique for culture of clinical urine samples Jen-Chyi Chang 1,2,
More informationEmergence of non-kpc carbapenemases: NDM and more
Emergence of non-kpc carbapenemases: NDM and more --- David Livermore Health Protection Agency, UK The first acquired carbapenemase to be recognised in gram-negative bacteria was IMP-1, a metallo-type,
More informationAminoglycoside Resistance in Gram-negative Bacilli
Korean J Clin Microbiol Vol. 12, No. 2, June, 2009 Aminoglycoside Resistance in Gram-negative Bacilli Yeon-Joon Park Department of Laboratory Medicine, College of Medicine, The Catholic University of Korea,
More informationRoula M. Abdel-Massih Dept. of Biology, University of Balamand, Lebanon
http://skinnywithfiber.org Roula M. Abdel-Massih Dept. of Biology, University of Balamand, Lebanon Ilex paraguariensis Classification and characteristics Family Aquifoliaceae Found mainly in South America
More informationUpdate on CLSI and EUCAST
Update on CLSI and EUCAST 1 Completed work» Cephalosporin breakpoints for Enterobacteriaceae ESBL screens MIC versus resistance mechanism» Carbapenem breakpoints for Enterobacteriaceae Modified Hodge Test»
More informationARTICLE IN PRESS International Journal of Antimicrobial Agents xxx (2010) xxx xxx
International Journal of Antimicrobial Agents xxx (2010) xxx xxx Contents lists available at ScienceDirect International Journal of Antimicrobial Agents journal homepage: http://www.elsevier.com/locate/ijantimicag
More informationIn Vitro Activity of Ceftazidime-Avibactam Against Isolates. in a Phase 3 Open-label Clinical Trial for Complicated
AAC Accepted Manuscript Posted Online 21 November 2016 Antimicrob. Agents Chemother. doi:10.1128/aac.01820-16 Copyright 2016, American Society for Microbiology. All Rights Reserved. 1 2 3 4 5 6 7 8 9 10
More informationPhenotypic Detection Methods of Carbapenemase Production in Enterobacteriaceae
ISSN: 2319-7706 Volume 4 Number 6 (2015) pp. 547-552 http://www.ijcmas.com Original Research Article Phenotypic Detection Methods of Carbapenemase Production in Enterobacteriaceae Sathya Pandurangan 1,
More informationSpread of carbapenems resistant Enterobacteriaceae in South Africa; report from National Antimicrobial Resistance Reference Laboratory
Spread of carbapenems resistant Enterobacteriaceae in South Africa; report from National Antimicrobial Resistance Reference Laboratory Olga Perovic*, Ashika Singh-Moodley, Samantha Iyaloo 5 th November
More information#Corresponding author: Pathology Department, Singapore General Hospital, 20 College. Road, Academia, Level 7, Diagnostics Tower, , Singapore
AAC Accepts, published online ahead of print on 21 October 2013 Antimicrob. Agents Chemother. doi:10.1128/aac.01754-13 Copyright 2013, American Society for Microbiology. All Rights Reserved. 1 Title: Escherichia
More informationGuidance on screening and confirmation of carbapenem resistant Enterobacteriacae (CRE) December 12, 2011
Guidance on screening and confirmation of carbapenem resistant Enterobacteriacae (CRE) December 12, 2011 Objectives: To discuss the guidelines for detection of CRE in the laboratory setting. To review
More informationBurns outbreaks - the UHB experience
Burns outbreaks - the UHB experience Dr Mark Garvey Principal Clinical Scientist in Microbiology Director of the Hospital Infection Research Laboratory Associate Director of Infection Prevention and Control
More informationRapid identification of emerging resistance in Gram negatives. Prof. Patrice Nordmann
Rapid identification of emerging resistance in Gram negatives Prof. Patrice Nordmann Emerging Resistance threats, CDC USA-2013 Enterobacteriaceae producing extendedspectrum β-lactamases (ESBL) Multi-resistant
More informationEfficacy Data. Disinfectant Cleaner & Odor Counteractant EPA REG. #
SENTS-ALE Hospital Disinfection (at 2 ounces per gallon)) Scents-Able is bactericidal according to the AOA Use Dilution Test method on hard inanimate surfaces modified in the presence of 5% organic serum
More informationUrinary Tract Infection and Pattern of Antibiotic Sensitivity in Hospitalized Patients with Diabetes Mellitus in Myanmar
Volume 2 Issue 1 2018 Page 147 to 153 Research Article Archives of Endocrinology and Diabetes Care Urinary Tract Infection and Pattern of Antibiotic Sensitivity in Hospitalized Patients with Diabetes Mellitus
More informationAnalysis of the common opportunistic pathogens
2009 12 4 4 Journal of Microbes and Infection, December 2009, Vol. 4, No. 4 241 1, 3 1, 2, 3, 1. ( ), 201508; 2., 200040; 3., 200032 :,,,,,,, ;, : ; ; Analysis of the common opportunistic pathogens SUN
More informationKlebsiella pneumoniae 21 PCR
2011 11 TEM-132 ESBL Klebsiella pneumoniae 1) 2) 1) 1) 3) 2) 1) 2) 3) 19 6 27 22 10 20 2003 4 2004 11 95 ceftazidime (CAZ) Klebsiella pneumoniae 21 PCR b- (ESBL) PCR (PFGE) PCR bla TEM-132 PFGE 19 TEM-132
More informationMedical School, University of East Anglia, Norwich NR4 7TJ, UK
J Antimicrob Chemother 2014; 69: 1050 1056 doi:10.1093/jac/dkt455 Advance Access publication 19 November 2013 Comparative in vitro activity of sulfametrole/ and and other agents against multiresistant
More informationActivity of tigecycline alone and in combination with colistin and meropenem against carbapenemase
Activity of tigecycline alone and in combination with colistin and meropenem against carbapenemase (KPC)-producing Enterobacteriaceae strains by time-kill assay Spyros Pournaras, Georgia Vrioni, Evangelia
More informationKENNEL KARE SC DISINFECTANT / CLEANER / DEODORIZER Efficacy Data EPA Reg. #
Inc. Efficacy: Hospital Disinfection (at ½ ounce per gallon) Kennel Kare SC is bactericidal according to the AOAC Use Dilution Test method on hard inanimate surfaces modified in the presence of 5% organic
More informationSensitive and specific Modified Hodge Test for KPC and metallo-beta-lactamase
JCM Accepts, published online ahead of print on 19 October 2011 J. Clin. Microbiol. doi:10.1128/jcm.05602-11 Copyright 2011, American Society for Microbiology and/or the Listed Authors/Institutions. All
More informationJournal of Infectious Diseases and
Journal of Infectious Diseases & Therapy ISSN: 2332-0877 Journal of Infectious Diseases and Therapy Santanirand et al., J Infect Dis Ther 2018, 6:5 DOI: 10.4172/2332-0877.1000378 Research Article Open
More informationTigecycline activity tested against 26, 474 bloodstream infection isolates: a collection from 6 continents
Diagnostic Microbiology and Infectious Disease 52 (2005) 181 186 www.elsevier.com/locate/diagmicrobio Tigecycline activity tested against 26, 474 bloodstream infection isolates: a collection from 6 continents
More informationORIGINAL ARTICLE SUSCEPTIBILITY PATTERNS IN GRAM NEGATIVE URINARY ISOLATES TO CIPROFLOXACIN, CO-TRIMOXAZOLE AND NITROFURANTOIN
SUSCEPTIBILITY PATTERNS IN GRAM NEGATIVE URINARY ISOLATES TO CIPROFLOXACIN, CO-TRIMOXAZOLE AND NITROFURANTOIN Anoop Sinha 1, Benny P V 2 HOW TO CITE THIS ARTICLE: Anoop Sinha, Benny PV. Susceptibility
More informationAn evaluation of 2.0 McFarland Etest method for detection of heterogeneous vancomycin-intermediate Staphylococcus aureus
Asian Biomedicine Vol. 4 No. 1 February 2010; 141-145 Brief communication (Original) An evaluation of 2.0 McFarland Etest method for detection of heterogeneous vancomycin-intermediate Staphylococcus aureus
More informationEscherichia coli b- Extended spectrum b-lactamase (ESBL) 8 (6.5 ), Cephalosporinase (Amp- Amp-C 2. IncF (FIA,FIB) group ESBL 6 Amp-C 4
2011 193 Escherichia coli b- 22 12 20 23 5 30 b- 2006 1 2009 9 744 Escherichia coli b- 4,211 E. coli 123 (2.9) 124 CAZ AZT MIC 2 mg/ml 12 (9.8) 13 Extended spectrum b-lactamase (ESBL) 8 (6.5), Cephalosporinase
More informationVeerle Compernolle, Gerda Verschraegen, and Geert Claeys* Department of Microbiology, Ghent University Hospital, Ghent, Belgium
JOURNAL OF CLINICAL MICROBIOLOGY, Jan. 2007, p. 154 158 Vol. 45, No. 1 0095-1137/07/$08.00 0 doi:10.1128/jcm.01115-06 Copyright 2007, American Society for Microbiology. All Rights Reserved. Combined Use
More informationOriginal Article Clinical Microbiology
Original Article Clinical Microbiology Ann Lab Med 2015;35:212-219 http://dx.doi.org/10.3343/alm.2015.35.2.212 ISSN 2234-3806 eissn 2234-3814 Combined Use of the Modified Hodge Test and Carbapenemase Inhibition
More informationUeli von Ah, Dieter Wirz, and A. U. Daniels*
JOURNAL OF CLINICAL MICROBIOLOGY, June 2008, p. 2083 2087 Vol. 46, No. 6 0095-1137/08/$08.00 0 doi:10.1128/jcm.00611-08 Copyright 2008, American Society for Microbiology. All Rights Reserved. Rapid Differentiation
More informationKENNEL KARE SC DISINFECTANT / CLEANER / DEODORIZER Efficacy Data EPA Reg. #
Inc. Efficacy: Disinfection (at ½ ounce per gallon) Kennel Kare SC is bactericidal according to the AOAC Use Dilution Test method on hard inanimate surfaces modified in the presence of 5% organic serum
More informationK. Lee, Y. S. Lim, D. Yong, J. H. Yum, and Y. Chong*
JOURNAL OF CLINICAL MICROBIOLOGY, Oct. 2003, p. 4623 4629 Vol. 41, No. 10 0095-1137/03/$08.00 0 DOI: 10.1128/JCM.41.10.4623 4629.2003 Copyright 2003, American Society for Microbiology. All Rights Reserved.
More informationBurns outbreaks - the UHB experience
Burns outbreaks - the UHB experience Dr Mark Garvey Mr Craig Bradley Principal Clinical Scientist in Microbiology Lead Nurse Infection Prevention Director of the Hospital Infection Research Laboratory
More informationPrevalence of Extended Spectrum -Lactamases In E.coli and Klebsiella spp. in a Tertiary Care Hospital
ISSN: 2319-7706 Volume 3 Number 10 (2014) pp. 474-478 http://www.ijcmas.com Original Research Article Prevalence of Extended Spectrum -Lactamases In E.coli and Klebsiella spp. in a Tertiary Care Hospital
More informationActivity of Ceftolozane/Tazobactam Against a Broad Spectrum of Recent Clinical Anaerobic Isolates
AAC Accepts, published online ahead of print on 25 November 2013 Antimicrob. Agents Chemother. doi:10.1128/aac.02253-13 Copyright 2013, American Society for Microbiology. All Rights Reserved. Activity
More informationStandardisation of testing for Carbapenemase Producing Organisms (CPO) in Scotland
Standardisation of testing for Carbapenemase Producing Organisms (CPO) in Scotland Version 1.0 7 June 2017 Revision Date June 2018 Scottish Microbiology and Virology Network (SMVN) SMVN Standardisation
More informationSpectrum of vancomycin and susceptibility testing
Spectrum of vancomycin and susceptibility testing Olivier Denis Service de Microbiologie Laboratoire de bactériologie Service de Microbiologie Hôpital Erasme Glycopeptides Vancomycin 1958 < Amycolatopsis
More informationAbstract. Introduction
ORIGINAL ARTICLE INFECTIOUS DISEASES Accuracy of American Thoracic Society/Infectious Diseases Society of America criteria in predicting infection or colonization with multidrug-resistant bacteria at intensive-care
More informationINFECTIOUS DISEASE. Page 2
Infectious disease Advantages OF TESTING INFECTIOUS DISEASE We are in the middle of a paradigm shift in infectious disease diagnostic testing. As we move from targeted infectious disease testing to a syndromic
More informationCAVIWIPES1. Technical Bulletin
CAVIWIPES1 Technical Bulletin CaviWipes1 Disinfecting Towelettes are non-woven disposable towelettes pre-saturated with CaviCide1. CaviWipes 1 are intended for use in health care settings such as hospitals,
More informationCarbapenemases in Enterobacteriaceae: Prof P. Nordmann Bicêtre hospital, South-Paris Med School
Carbapenemases in Enterobacteriaceae: 2012 Prof P. Nordmann Bicêtre hospital, South-Paris Med School March 21, 2012 Trends in Molecular Medecine NDM IMP OXA-48 KPC VIM ALERT VI M KPC KPC NDM I MP OXA-
More informationRAPID COMMUNICATION. Maura S. de Oliveira, I Silvia Figueiredo Costa, II Ewerton de Pedri, II Inneke van der Heijden, II Anna Sara S.
RAPID COMMUNICATION The minimal inhibitory concentration for sulbactam was not associated with the outcome of infections caused by carbapenem-resistant Acinetobacter sp. treated with ampicillin/sulbactam
More informationReceived 21 April 1997/Returned for modification 30 June 1997/Accepted 28 August 1997
JOURNAL OF CLINICAL MICROBIOLOGY, Dec. 1997, p. 3258 3263 Vol. 35, No. 12 0095-1137/97/$04.00 0 Copyright 1997, American Society for Microbiology Comparison of Agar Dilution, Broth Microdilution, E-Test,
More informationEUCAST Frequently Asked Questions. by author. Rafael Cantón Hospital Universitario Ramón y Cajal, Madrid, Spain EUCAST Clinical Data Coordinator
EUCAST Frequently Asked Questions Rafael Cantón Hospital Universitario Ramón y Cajal, Madrid, Spain EUCAST Clinical Data Coordinator Erika Matuschek EUCAST Development Laboratory, Växjö Sweden Monday 24
More informationSuccessful treatment of pan - resistant pseudomonas Aerugınosa menıngıtıs wıth ıntrathecal polymyxın b therapy
ISPUB.COM The Internet Journal of Infectious Diseases Volume 7 Number 2 Successful treatment of pan - resistant pseudomonas Aerugınosa menıngıtıs wıth ıntrathecal polymyxın b F Simsek, T Yildirmak, G Cetmeli,
More informationEvaluation of Six Phenotypic Methods for the Detection of Carbapenemases in Gram-Negative Bacteria With Characterized Resistance Mechanisms
Original Article Clinical Microbiology Ann Lab Med 2017;37:305-312 https://doi.org/10.3343/alm.2017.37.4.305 ISSN 2234-3806 eissn 2234-3814 Evaluation of Six Phenotypic Methods for the Detection of Carbapenemases
More informationProf George Dimopoulos MD,PhD,FCCP
14 th Symposium on Infections and Sepsis Porto, 1-3 April 2009 Outbreak control Prof George Dimopoulos MD,PhD,FCCP Department of Respiratory and Intensive Care University Hospital ATTIKON Medical School,
More informationAntimicrobial Activity and Spectrum of PPI-0903M (T-91825), a Novel Cephalosporin, Tested against a Worldwide Collection of Clinical Strains
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Aug. 2005, p. 3501 3512 Vol. 49, No. 8 0066-4804/05/$08.00 0 doi:10.1128/aac.49.8.3501 3512.2005 Copyright 2005, American Society for Microbiology. All Rights Reserved.
More informationSurveillance of Healthcare Associated Infections in Scottish Intensive Care Units
Surveillance of Healthcare Associated Infections in Scottish Intensive Care Units Annual report of data from January 2010 to December 2010 Scottish Intensive Care Society Audit Group 1 Health Protection
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Doribax 250 mg powder for solution for infusion 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each vial contains doripenem monohydrate
More informationEmergence of Klebsiella pneumoniae ST258 with KPC-2 in Hong Kong. Title. Ho, PL; Tse, CWS; Lai, EL; Lo, WU; Chow, KH
Title Emergence of Klebsiella pneumoniae ST258 with KPC-2 in Hong Kong Author(s) Ho, PL; Tse, CWS; Lai, EL; Lo, WU; Chow, KH Citation International Journal Of Antimicrobial Agents, 2011, v. 37 n. 4, p.
More informationInternational transfer of NDM-1-producing Klebsiella. pneumoniae from Iraq to France
AAC Accepts, published online ahead of print on 18 January 2011 Antimicrob. Agents Chemother. doi:10.1128/aac.01761-10 Copyright 2011, American Society for Microbiology and/or the Listed Authors/Institutions.
More informationResistance to Polymyxins in France
Resistance to Polymyxins in France Paris Prof. Patrice Nordmann NDM producers in Enterobacteriaceae The polymyxins; colistin and polymyxin B Colistin - Synthesis by Bacillus polymyxa spp colistinus -
More informationmolecules ISSN Article
Molecules 2014, 19, 12630-12639; doi:10.3390/molecules190812630 OPEN ACCESS molecules ISSN 1420-3049 www.mdpi.com/journal/molecules Article Studies of the in Vitro Antibacterial Activities of Several Polyphenols
More informationResearch Article PhenotypicDetectionofMetallo-β-Lactamase in Imipenem-Resistant Pseudomonas aeruginosa
The Scientific World Journal Volume 2012, Article ID 654939, 7 pages doi:10.1100/2012/654939 The cientificworldjournal Research Article PhenotypicDetectionofMetallo-β-Lactamase in Imipenem-Resistant Pseudomonas
More informationWhat is new in EUCAST South Africa, May, Gunnar Kahlmeter EUCAST Technical Data Coordinator and Webmaster Sweden
What is new in EUCAST 2016 17 South Africa, May, 2016 Gunnar Kahlmeter EUCAST Technical Data Coordinator and Webmaster Sweden What is new in EUCAST 2016/17? New organisms with breakpoints (Addendum 2016)
More informationExpert rules. for Gram-negatives
Academic Perspective in Expert rules Emerging Issues of Resistance in Gram-ve Bacteria for Gram-negatives Trevor Winstanley Sheffield Teaching Hospitals Presented on behalf of David Livermore University
More informationBiofilms: Álvaro Pascual MD, PhD Department of Microbiology
Biofilms: Role on Pathogenesis and Treatment of UTIs. Álvaro Pascual MD, PhD Department of Microbiology University of Seville. Spain. Medical devices-related infections 1. 35 millions/year in USA 2. Most
More information320 MBIO Microbial Diagnosis. Aljawharah F. Alabbad Noorah A. Alkubaisi 2017
320 MBIO Microbial Diagnosis Aljawharah F. Alabbad Noorah A. Alkubaisi 2017 Pathogens of the Urinary tract The urinary system is composed of organs that regulate the chemical composition and volume of
More informationBelow is an overview of the oral and poster presentations featuring cefiderocol and S at IDWeek 2017:
SHIONOGI TO HIGHLIGHT RESEARCH ON CEFIDEROCOL (S-649266), A SIDEROPHORE CEPHALOSPORIN, AND S-033188, A CAP-DEPENDENT ENDONUCLEASE INHIBITOR FOR TREATMENT OF INFLUENZA, AT IDWEEK 2017 OSAKA, Japan and FLORHAM
More informationHetero- and adaptive resistance to polymyxin B in OXA-23-producing carbapenem-resistant Acinetobacter baumannii isolates
Barin et al. Annals of Clinical Microbiology and Antimicrobials 2013, 12:15 RESEARCH Open Access Hetero- and adaptive resistance to polymyxin B in OXA-23-producing carbapenem-resistant Acinetobacter baumannii
More informationCarbapenemase Producing Enterobacteriaceae: Screening
Carbapenemase Producing Enterobacteriaceae: Screening Dr David Harvey Consultant Microbiology and Infection Prevention and Control Nov 2015 Aims Is CPE a problem? Does screening have the potential to help?
More information